Download PDF
Horm Metab Res 2009; 41(2): 123-131
DOI: 10.1055/s-0028-1119378
Review

© Georg Thieme Verlag KG Stuttgart · New York

Cardiovascular Effects of Disturbed Insulin Activity in Metabolic Syndrome and in Type 2 Diabetic Patients

T. Forst 1 , C. Hohberg 1 , A. Pfützner 1
  • 1Institute for Clinical Research and Development, Mainz, Germany
Further Information

Publication History

received 22.09.2008

accepted 08.12.2008

Publication Date:
12 February 2009 (online)

Also available at
    Permissions and Reprints

Abstract

The metabolic syndrome is associated with an excess of increase in cardiovascular complications. Disturbances in insulin efficacy and insulin secretion are major features of the metabolic syndrome and might precede the development of diabetes mellitus by decades. Recent investigations highlighted the link between disturbances in insulin physiology and subsequent mechanisms of atherosclerosis. Insulin resistance is an early feature of increasing visceral adipose tissue and is directly associated to the activation of a couple of atherogenic pathways, including inflammation and the activation of the mitogen-activated proteinkinase pathway accelerating the atherogenic process. In patients with normal beta-cell function, insulin resistance is compensated by increased insulin release from the beta cells to keep blood glucose levels compensated. In those patients, genetically predisposed to type 2 diabetes, beta-cell function deteriorates with the development of timely, qualitative and quantitative insulin secretion disorders, and the development of overt diabetes mellitus. The coexistence of insulin resistance with functional beta cell failure results in loss of blood glucose control especially after a meal and increases the cardiovascular risk of these patients far beyond the increased glucose levels.

Key words

diabetes mellitus type 2 - insulin resistance - insulin secretion

References

  • 1 Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals.  Endocrinol Metab Clin North Am. 2004;  33 283-303
    CrossrefPubMedGoogle Scholar
  • 2 Gaal LF Van, Mertens IL, Block CE De. Mechanisms linking obesity with cardiovascular disease.  Nature. 2006;  444 875-880
    CrossrefPubMedGoogle Scholar
  • 3 Hara T, Fujiwara H, Shoji T, Mimura T, Nakao H, Fujimoto S. Decreased plasma adiponectin levels in young obese males.  J Atheroscler Thromb. 2003;  10 234-238
    PubMedGoogle Scholar
  • 4 Kern PA, Gregorio GB Di, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression.  Diabetes. 2003;  52 1779-1785
    CrossrefPubMedGoogle Scholar
  • 5 Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose.  Diabetes. 2000;  49 1751-1760
    CrossrefPubMedGoogle Scholar
  • 6 Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes.  Diabetes. 2002;  51 ((Suppl. 1)) S109-S116
    CrossrefPubMedGoogle Scholar
  • 7 Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, Williams DE, Flegal KM, Narayan KM, Williamson DF. Secular trends in cardiovascular disease risk factors according to body mass index in US adults.  JAMA. 2005;  293 1868-1874
    CrossrefPubMedGoogle Scholar
  • 8 Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes.  Int J Obes Relat Metab Disord. 2003;  46 3-19
    CrossrefPubMedGoogle Scholar
  • 9 Ferrannini E, Mari A. Beta cell function and its relation to insulin action in humans: a critical appraisal.  Int J Obes Relat Metab Disord. 2004;  47 943-956
    CrossrefPubMedGoogle Scholar
  • 10 Al Suwaidi J, Higano ST, Holmes  Jr  DR, Lennon R, Lerman A. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries.  J Am Coll Cardiol. 2001;  37 1523-1528
    CrossrefPubMedGoogle Scholar
  • 11 Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G, Armellini F, Bosello O, Lechi A. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity.  Int J Obes Relat Metab Disord. 1999;  23 936-942
    CrossrefPubMedGoogle Scholar
  • 12 Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.  Circulation. 2006;  113 1888-1904
    CrossrefPubMedGoogle Scholar
  • 13 Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism.  Nature. 2001;  414 799-806
    CrossrefPubMedGoogle Scholar
  • 14 Montagnani M, Quon MJ. Insulin action in vascular endothelium: potential mechanisms linking insulin resistance with hypertension.  Diabetes Obes Metab. 2000;  2 285-292
    CrossrefPubMedGoogle Scholar
  • 15 Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin.  Circulation. 2000;  101 676-681
    PubMedGoogle Scholar
  • 16 Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells.  Circulation. 2000;  101 1539-1545
    CrossrefPubMedGoogle Scholar
  • 17 Montagnani M, Ravichandran LV, Chen H, Esposito DL, Quon MJ. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells.  Mol Endocrinol. 2002;  16 1931-1942
    CrossrefPubMedGoogle Scholar
  • 18 Hsueh WA, Lyon CJ, Quinones MJ. Insulin resistance and the endothelium.  Am J Med. 2004;  117 109-117
    CrossrefPubMedGoogle Scholar
  • 19 Loscalzo J. Nitric oxide and vascular disease.  N Engl J Med. 1995;  333 251-253
    CrossrefPubMedGoogle Scholar
  • 20 Loscalzo J. Antiplatelet and antithrombotic effects of organic nitrates.  Am J Cardiol. 1992;  70 18B-22B
    CrossrefPubMedGoogle Scholar
  • 21 Scognamiglio R, Negut C, Kreutzenberg SV De, Tiengo A, Avogaro A. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients.  Circulation. 2005;  112 179-184
    CrossrefPubMedGoogle Scholar
  • 22 Forst T, Kunt T, Pohlmann T, Goitom K, Löbig M, Engelbach M, Beyer J, Pfützner A. Microvascular skin blood flow following the ingestion of 75 g Glucose in healthy individuals.  Exp Clin Endocrinol Diabetes. 1998;  106 453-458
    PubMedGoogle Scholar
  • 23 Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle.  Diabetes. 2006;  55 1436-1442
    CrossrefPubMedGoogle Scholar
  • 24 Wiggam MI, Hunter SJ, Ennis CN, Sheridan B, Atkinson AB, Bell PM. Insulin action and skeletal muscle blood flow in patients with Type 1 diabetes and microalbuminuria.  Diabetes Res Clin Pract. 2001;  53 73-83
    CrossrefPubMedGoogle Scholar
  • 25 Pitkanen OP, Nuutila P, Raitakari OT, Ronnemaa T, Koskinen PJ, Iida H, Lehtimaki TJ, Laine HK, Takala T, Viikari JS, Knuuti J. Coronary flow reserve is reduced in young men with IDDM.  Diabetes. 1998;  47 248-254
    CrossrefPubMedGoogle Scholar
  • 26 Sundell J, Knuuti J. Insulin and myocardial blood flow.  Cardiovasc Res. 2003;  57 312-319
    CrossrefPubMedGoogle Scholar
  • 27 Gudbjornsdottir S, Sjostrand M, Strindberg L, Lonnroth P. Decreased muscle capillary permeability surface area in type 2 diabetic subjects.  J Clin Endocrinol Metab. 2005;  90 1078-1082
    CrossrefPubMedGoogle Scholar
  • 28 Hermann TS, Li W, Dominguez H, Ihlemann N, Rask-Madsen C, Major-Pedersen A, Nielsen DB, Hansen KW, Hawkins M, Kober L, Torp-Pedersen C. Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes.  J Clin Endocrinol Metab. 2006;  91 1001-1008
    PubMedGoogle Scholar
  • 29 Rask-Madsen C, Ihlemann N, Krarup T, Christiansen E, Kober L, Nervil KC, Torp-Pedersen C. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease.  Diabetes. 2001;  50 2611-2618
    CrossrefPubMedGoogle Scholar
  • 30 Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction.  Circulation. 2001;  103 1410-1415
    CrossrefPubMedGoogle Scholar
  • 31 Verma S, Yao L, Stewart DJ, Dumont AS, Anderson TJ, MacNeill JH. Endothelin antagonism uncovers insulin-mediated vasorelaxation in vitro and in vivo.  Hypertension. 2001;  37 328-333
    PubMedGoogle Scholar
  • 32 Eringa EC, Stehouwer CD, Nieuw Amerongen GP, Ouwehand L, Westerhof N, Sipkema P. Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium.  Am J Physiol Heart Circ Physiol. 2004;  287 H2043-H2048
    CrossrefPubMedGoogle Scholar
  • 33 Prior JO, Quinones MJ, Hernandez-Pampaloni M, Facta AD, Schindler TH, Sayre JW, Hsueh WA, Schelbert HR. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus.  Circulation. 2005;  111 2291-2298
    CrossrefPubMedGoogle Scholar
  • 34 Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia.  Diabetes. 2000;  49 2094-2101
    CrossrefPubMedGoogle Scholar
  • 35 Eringa EC, Stehouwer CD, Roos MH, Westerhof N, Sipkema P. Selective resistance to vasoactive effects of insulin in muscle resistance arteries of obese Zucker (fa/fa) rats.  Am J Physiol Endocrinol Metab. 2007;  293 E1134-E1139
    CrossrefPubMedGoogle Scholar
  • 36 Potenza MA, Marasciulo FL, Chieppa DM, Brigiani GS, Formoso G, Quon MJ, Montagnani M. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production.  Am J Physiol Heart Circ Physiol. 2005;  289 H813-H822
    CrossrefPubMedGoogle Scholar
  • 37 Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells.  J Biol Chem. 2002;  277 1794-1799
    CrossrefPubMedGoogle Scholar
  • 38 Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle.  J Clin Invest. 2000;  105 311-320
    CrossrefPubMedGoogle Scholar
  • 39 Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes.  Diabetes. 2004;  53 2060-2066
    CrossrefPubMedGoogle Scholar
  • 40 Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes.  Diabetes. 2002;  51 3517-3523
    CrossrefPubMedGoogle Scholar
  • 41 Rahmouni K, Morgan DA, Morgan GM, Liu X, Sigmund CD, Mark AL, Haynes WG. Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin.  J Clin Invest. 2004;  114 652-658
    PubMedGoogle Scholar
  • 42 Oh JY, Barrett-Connor E, Wedick NM. Sex differences in the association between proinsulin and intact insulin with coronary heart disease in nondiabetic older adults: the Rancho Bernardo Study.  Circulation. 2002;  105 1311-1316
    CrossrefPubMedGoogle Scholar
  • 43 Roder ME, Porte  Jr  D, Schwartz RS, Kahn SE. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.  J Clin Endocrinol Metab. 1998;  83 604-608
    CrossrefPubMedGoogle Scholar
  • 44 Hostens K, Ling Z, Schravendijk C Van, Pipeleers D. Prolonged exposure of human beta-cells to high glucose increases their release of proinsulin during acute stimulation with glucose or arginine.  J Clin Endocrinol Metab. 1999;  84 1386-1390
    CrossrefPubMedGoogle Scholar
  • 45 Seaquist ER, Kahn SE, Clark PM, Hales CN, Porte  Jr  D, Robertson RP. Hyperproinsulinemia is associated with increased beta cell demand after hemipancreatectomy in humans.  J Clin Invest. 1996;  97 455-460
    CrossrefPubMedGoogle Scholar
  • 46 Haffner SM, Mykkanen L, Stern MP, Valdez RA, Heisserman JA, Bowsher RR. Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects.  Diabetes. 1993;  42 1297-1302
    CrossrefPubMedGoogle Scholar
  • 47 Pfützner A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T, Lubben G, Forst T. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes.  Diabetes Care. 2004;  27 682-687
    CrossrefPubMedGoogle Scholar
  • 48 Langenfeld MR, Forst T, Standl E, Strotmann HJ, Lubben G, Pahler S, Kann P, Pfützner A. IRIS II Study: Sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance.  Diabetes Technol Ther. 2004;  6 836-843
    CrossrefPubMedGoogle Scholar
  • 49 Pfützner A, Standl E, Hohberg C, Konrad T, Strotmann HJ, Lubben G, Langenfeld MR, Schulze J, Forst T. IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design.  Diabetes Technol Ther. 2005;  7 478-486
    CrossrefPubMedGoogle Scholar
  • 50 Kirchhoff K, Machicao F, Haupt A, Schafer SA, Tschritter O, Staiger H, Stefan N, Haring HU, Fritsche A. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion.  Int J Obes Relat Metab Disord. 2008;  51 597-601
    PubMedGoogle Scholar
  • 51 Yudkin JS, May M, Elwood P, Yarnell JW, Greenwood R, Davey SG. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study.  Diabetologia. 2002;  45 327-336
    CrossrefPubMedGoogle Scholar
  • 52 Wohlin M, Sundstrom J, Arnlov J, Andren B, Zethelius B, Lind L. Impaired insulin sensitivity is an independent predictor of common carotid intima-media thickness in a population sample of elderly men.  Atherosclerosis. 2003;  170 181-185
    CrossrefPubMedGoogle Scholar
  • 53 Lindahl B, Dinesen B, Eliasson M, Roder M, Hallmans G, Stegmayr B. High proinsulin levels precede first-ever stroke in a nondiabetic population.  Stroke. 2000;  31 2936-2941
    PubMedGoogle Scholar
  • 54 Alssema M, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study.  Diabetes Care. 2005;  28 860-865
    CrossrefPubMedGoogle Scholar
  • 55 Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR, Anderson JH. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience.  Diabetes Care. 1992;  15 666-692
    CrossrefPubMedGoogle Scholar
  • 56 Lindahl B, Dinesen B, Eliasson M, Roder M, Jansson JH, Huhtasaari F, Hallmans G. High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population.  Metabolism. 1999;  48 1197-1202
    CrossrefPubMedGoogle Scholar
  • 57 Forst T, Pfützner A, Lubben G, Weber M, Marx N, Karagiannis E, Koehler C, Baurecht W, Hohberg C, Hanefeld M. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk–the PIOSTAT Study.  Metabolism. 2007;  56 491-496
    CrossrefPubMedGoogle Scholar
  • 58 Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30.  J Clin Invest. 2001;  108 1875-1881
    CrossrefPubMedGoogle Scholar
  • 59 Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.  Nat Med. 2002;  8 1288-1295
    CrossrefPubMedGoogle Scholar
  • 60 Mitsuhashi N, Onuma T, Kubo S, Takayanagi N, Honda M, Kawamori R. Coronary artery disease and carotid artery intima-media thickness in Japanese type 2 diabetic patients.  Diabetes Care. 2002;  25 1308-1312
    CrossrefPubMedGoogle Scholar
  • 61 Haffner SM, D’Agostino R, Mykkanen L, Hales CN, Savage PJ, Bergman RN, O’Leary D, Rewers M, Selby J, Tracy R, Saad MF. Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study.  Stroke. 1998;  29 1498-1503
    PubMedGoogle Scholar
  • 62 Forst T, Hohberg C, Fuellert SD, Lubben G, Konrad T, Lobig M, Weber MM, Sachara C, Gottschall V, Pfützner A. Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.  Horm Metab Res. 2005;  37 521-527
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Jia EZ, Yang ZJ, Zhu TB, Wang LS, Chen B, Cao KJ, Huang J, Ma WZ. Proinsulin Is an Independent Predictor of the Angiographical Characteristics of Coronary Atherosclerosis.  Cardiology. 2007;  110 106-111
    PubMedGoogle Scholar
  • 64 Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.  Circulation. 1994;  89 321-330
    PubMedGoogle Scholar
  • 65 Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.  Circulation. 1995;  91 764-770
    CrossrefPubMedGoogle Scholar
  • 66 Nordt TK, Bode C, Sobel BE. Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor Type I by proinsulin.  Int J Obes Relat Metab Disord. 2001;  44 1121-1124
    PubMedGoogle Scholar
  • 67 Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease.  Am J Med. 2003;  115 ((Suppl. 8A)) 62S-68S
    PubMedGoogle Scholar
  • 68 Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, Galan BE de, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.  N Engl J Med. 2008;  358 2560-2572
    CrossrefPubMedGoogle Scholar
  • 69 Gerstein HC, Miller ME, Byington RP, Goff  Jr  DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm  Jr  RH, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes.  N Engl J Med. 2008;  358 2545-2559
    CrossrefPubMedGoogle Scholar
  • 70 Jadhav S, Petrie J, Ferrell W, Cobbe S, Sattar N. Insulin resistance as a contributor to myocardial ischaemia independent of obstructive coronary atheroma: a role for insulin sensitisation?.  Heart. 2004;  90 1379-1383
    CrossrefPubMedGoogle Scholar
  • 71 Verma S, Yao L, Dumont AS, MacNeill JH. Metformin treatment corrects vascular insulin resistance in hypertension.  J Hypertens. 2000;  18 1445-1450
    CrossrefPubMedGoogle Scholar
  • 72 UKPDS Study Group. . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet. 1998;  352 854-865
    CrossrefPubMedGoogle Scholar
  • 73 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes.  N Engl J Med. 2008;  359 1577-1589
    CrossrefPubMedGoogle Scholar
  • 74 Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect.  Diabetes Care. 2003;  26 2493-2499
    CrossrefPubMedGoogle Scholar
  • 75 Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.  Diabetes Care. 2001;  24 710-719
    CrossrefPubMedGoogle Scholar
  • 76 Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH. QUARTET Study Group . One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.  Diabetes Care. 2004;  27 141-147
    CrossrefPubMedGoogle Scholar
  • 77 Pfützner A, Hohberg C, Lubben G, Pahler S, Pfützner AH, Kann P, Forst T. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control.  Horm Metab Res. 2005;  37 510-515
    Article in Thieme ConnectPubMedGoogle Scholar
  • 78 Forst T, Karagiannis E, Lubben G, Hohberg C, Schondorf T, Dikta G, Drexler M, Morcos M, Danschel W, Borchert M, Pfützner A. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease.  Atherosclerosis. 2008;  197 311-317
    CrossrefPubMedGoogle Scholar
  • 79 Hanefeld M, Marx N, Pfützner A, Baurecht W, Lubben G, Karagiannis E, Stier U, Forst T. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.  J Am Coll Cardiol. 2007;  49 290-297
    CrossrefPubMedGoogle Scholar
  • 80 Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.  Diabetes Care. 2004;  27 484-490
    CrossrefPubMedGoogle Scholar
  • 81 Vinik AI, Stansberry KB, Barlow PM. Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus.  J Diabetes Complications. 2003;  17 279-285
    CrossrefPubMedGoogle Scholar
  • 82 Forst T, Lubben G, Hohberg C, Kann P, Sachara C, Gottschall V, Friedrich C, Rosskopf R, Pfützner A. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.  Microcirculation. 2005;  12 543-550
    CrossrefPubMedGoogle Scholar
  • 83 Potenza MA, Marasciulo FL, Tarquinio M, Quon MJ, Montagnani M. Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance.  Diabetes. 2006;  55 3594-3603
    CrossrefPubMedGoogle Scholar
  • 84 Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.  Nature. 1998;  391 82-86
    CrossrefPubMedGoogle Scholar
  • 85 Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.  Circulation. 2000;  101 235-238
    CrossrefPubMedGoogle Scholar
  • 86 O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson  Jr  SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group.  N Engl J Med. 1999;  340 14-22
    CrossrefPubMedGoogle Scholar
  • 87 Touboul PJ, Elbaz A, Koller C, Lucas C, Adrai V, Chedru F, Amarenco P. Common carotid artery intima-media thickness and brain infarction: the Etude du Profil Genetique de l’Infarctus Cerebral (GENIC) case-control study. The GENIC Investigators.  Circulation. 2000;  102 313-318
    PubMedGoogle Scholar
  • 88 Nakamura T, Matsuda T, Kawagoe Y, Ogawa H, Takahashi Y, Sekizuka K, Koide H. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients.  Metabolism. 2004;  53 1382-1386
    CrossrefPubMedGoogle Scholar
  • 89 Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD, Sachara C, Pfützner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.  Circulation. 2005;  111 2525-2531
    CrossrefPubMedGoogle Scholar
  • 90 Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, Larochelliere R De, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.  JAMA. 2008;  299 1561-1573
    CrossrefPubMedGoogle Scholar
  • 91 Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.  Lancet. 2005;  366 1279-1289
    CrossrefPubMedGoogle Scholar
  • 92 Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.  J Am Coll Cardiol. 2007;  49 1772-1780
    CrossrefPubMedGoogle Scholar
  • 93 Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.  Diabet Med. 1998;  15 297-303
    CrossrefPubMedGoogle Scholar
  • 94 Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.  N Engl J Med. 2006;  355 2427-2443
    CrossrefPubMedGoogle Scholar
  • 95 Aston-Mourney K, Proietto J, Morahan G, Andrikopoulos S. Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin.  Int J Obes Relat Metab Disord. 2008;  51 540-545
    PubMedGoogle Scholar
  • 96 Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets.  J Clin Endocrinol Metab. 2005;  90 501-506
    CrossrefPubMedGoogle Scholar
  • 97 Alvarsson M, Sundkvist G, Lager I, Berntorp K, Fernqvist-Forbes E, Steen L, Orn T, Holberg MA, Kirksaether N, Grill V. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up.  Diabetes Obes Metab. 2008;  10 421-429
    CrossrefPubMedGoogle Scholar
  • 98 Takahashi A, Nagashima K, Hamasaki A, Kuwamura N, Kawasaki Y, Ikeda H, Yamada Y, Inagaki N, Seino Y. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase.  Diabetes Res Clin Pract. 2007;  77 343-350
    CrossrefPubMedGoogle Scholar
  • 99 Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP. Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus.  Diabet Med. 1994;  11 293-298
    CrossrefPubMedGoogle Scholar
  • 100 Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes.  Pharmacoepidemiol Drug Saf. 2008;  17 753-759
    CrossrefPubMedGoogle Scholar
  • 101 Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies.  Diabetes Care. 2008;  31 1672-1678
    CrossrefPubMedGoogle Scholar
  • 102 Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.  Int J Obes Relat Metab Disord. 2006;  49 930-936
    CrossrefPubMedGoogle Scholar
  • 103 Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.  Diabetes Care. 2002;  25 2244-2248
    CrossrefPubMedGoogle Scholar
  • 104 Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.  CMAJ. 2006;  174 169-174
    CrossrefPubMedGoogle Scholar
  • 105 UK Prospective Diabetes Study (UKPDS) Group. . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
    CrossrefPubMedGoogle Scholar
  • 106 Fisman EZ, Tenenbaum A, Boyko V, Benderly M, Adler Y, Friedensohn A, Kohanovski M, Rotzak R, Schneider H, Behar S, Motro M. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up.  Clin Cardiol. 2001;  24 151-158
    CrossrefPubMedGoogle Scholar
  • 107 Stumvoll M, Fritsche A, Stefan N, Hardt E, Haring H. Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction.  J Clin Endocrinol Metab. 2001;  86 1235-1239
    CrossrefPubMedGoogle Scholar
  • 108 Fritsche A, Madaus A, Stefan N, Tschritter O, Maerker E, Teigeler A, Haring H, Stumvoll M. Relationships among age, proinsulin conversion, and beta-cell function in nondiabetic humans.  Diabetes. 2002;  51 ((Suppl. 1)) S234-S239
    CrossrefPubMedGoogle Scholar
  • 109 DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.  Diabetes Care. 2005;  28 1092-1100
    CrossrefPubMedGoogle Scholar
  • 110 Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.  Diabetes Care. 2006;  29 2638-2643
    CrossrefPubMedGoogle Scholar
  • 111 Stolar MW, Hoogwerf BJ, Gorshow SM, Boyle PJ, Wales DO. Managing type 2 diabetes: going beyond glycemic control.  J Manag Care Pharm. 2008;  14 s2-s19
    PubMedGoogle Scholar
  • 112 Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.  Eur Heart J. 2008;  29 166-176
    PubMedGoogle Scholar
  • 113 Pfützner A, Lorra B, Abdollahnia MR, Kann PH, Mathieu D, Pehnert C, Oligschleger C, Kaiser M, Forst T. The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus.  Diabetes Technol Ther. 2006;  8 375-384
    CrossrefPubMedGoogle Scholar
  • 114 Forst T, Pohlmann T, Kazda Ch, Welter K, Langer F, Forst S, Pfützner A. The impact of insulin lispro and regular insulin on postprandial endothelial function and microvascular blood flow in type 1 diabetic patients.  Diabetes. 2003;  51 ((Suppl. 2)) A 292
    PubMedGoogle Scholar
  • 115 Scognamiglio R, Negut C, Kreutzenberg SV De, Tiengo A, Avogaro A. Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients.  Diabetes Care. 2006;  29 95-100
    CrossrefPubMedGoogle Scholar
  • 116 Hohberg C, Forst T, Larbig M, Safinowski M, Diessel S, Hehenwarter S, Weber MM, Schondorf T, Pfützner A. Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial state.  Diabetes Care. 2008;  31 1021-1025
    CrossrefPubMedGoogle Scholar
  • 117 Piatti PM, Monti LD, Conti M, Baruffaldi L, Galli L, Phan CV, Guazzini B, Pontiroli AE, Pozza G. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans.  Diabetes. 1996;  45 316-321
    CrossrefPubMedGoogle Scholar
  • 118 Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin.  Endocr Rev. 2007;  28 463-491
    CrossrefPubMedGoogle Scholar
  • 119 Eurich DT, MacAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.  BMJ. 2007;  335 497
    CrossrefPubMedGoogle Scholar
  • 120 Anselmino M, Ohrvik J, Malmberg K, Standl E, Ryden L. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart.  Eur Heart J. 2008;  29 177-184
    PubMedGoogle Scholar
  • 121 Nagi DK, Knowler WC, Mohamed-Ali V, Bennett PH, Yudkin JS. Intact proinsulin, des 31,32 proinsulin, and specific insulin concentrations among nondiabetic and diabetic subjects in populations at varying risk of type 2 diabetes.  Diabetes Care. 1998;  21 127-133
    CrossrefPubMedGoogle Scholar
  • 122 Mykkanen L, Zaccaro DJ, Hales CN, Festa A, Haffner SM. The relation of proinsulin and insulin to insulin sensitivity and acute insulin response in subjects with newly diagnosed type II diabetes: the Insulin Resistance Atherosclerosis Study.  Diabetologia. 1999;  42 1060-1066
    CrossrefPubMedGoogle Scholar
  • 123 Pfützner A, Pfützner AH, Larbig M, Forst T. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus.  Diabetes Technol Ther. 2004;  6 405-412
    CrossrefPubMedGoogle Scholar

Correspondence

T. ForstMD 

Professor Internal Medicine

Institute for Clinical Research and Development

Parcusstraße 8

55116 Mainz

Germany

Phone: +49/6131/576 36 13

Fax: +49/6131/576 36 11

Email: thomasf@ikfe.de